Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 10,816 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Developmental Defect Clear all
Completed Phase 3 Interventional Results available

A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

NCT00912093
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Icatibant, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
39
States / cities
Alabaster, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 31, 2026, 10:34 AM EDT
Completed Phase 1 Interventional

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT04271514
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RPT193, Placebo
Drug
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
13
States / cities
Anniston, Alabama • Scottsdale, Arizona • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 31, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

NCT03233204
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma, Malignant Glioma, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Childhood Malignant Germ Cell Tumor, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Rhabdoid Tumor, Wilms Tumor
Interventions
Olaparib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
111
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 31, 2026, 10:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

NCT06138639
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
SGT-003
Genetic
Lead sponsor
Solid Biosciences Inc.
Industry
Eligibility
0 Years to 17 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
12
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 31, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

NCT03562377
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine
Drug · Biological
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 54 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 31, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

NCT01946412
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Birmingham, Alabama • Denver, Colorado • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 31, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

NCT03107611
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream, 1%, Placebo Cream
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
8 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
25
States / cities
Boynton Beach, Florida • Coral Gables, Florida • Miami, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 31, 2026, 10:34 AM EDT
Completed No phase listed Observational Results available

Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis

NCT03801993
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Chris Goss
Other
Eligibility
2 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
26
States / cities
Palo Alto, California • Hartford, Connecticut • Washington D.C., District of Columbia + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 31, 2026, 10:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurodevelopment and Neuroimaging in Parenterally-fed Infants and Young Children

NCT00392730
View directory record Official record
Conditions
Parenteral Nutrition, Necrotizing Enterocolitis, Digestive System Abnormalities, Cholestasis
Interventions
Remove Mn from PN if evidence of increased brain Mn on MRI
Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
30 Days to 6 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 31, 2026, 10:34 AM EDT
Completed No phase listed Observational

Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children

NCT02728128
View directory record Official record
Conditions
Pediatrics, Heart Failure, Congenital Heart Disease, Therapeutics
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 18 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 31, 2026, 10:34 AM EDT
Completed No phase listed Observational

Study of Kidney Tumors in Younger Patients

NCT00898365
View directory record Official record
Conditions
Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor, Angiolipoma, Cellular Congenital Mesoblastic Nephroma, Classic Congenital Mesoblastic Nephroma, Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma, Cystic Partially Differentiated Kidney Nephroblastoma, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Extrarenal Rhabdoid Tumor, Kidney Medullary Carcinoma, Kidney Neoplasm, Kidney Oncocytoma, Kidney Wilms Tumor, Metanephric Adenofibroma, Metanephric Adenoma, Metanephric Stromal Tumor, Metanephric Tumor, Mixed Congenital Mesoblastic Nephroma, Ossifying Renal Tumor of Infancy, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Rhabdoid Tumor of the Kidney, Wilms Tumor
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
214
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 31, 2026, 10:34 AM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia

NCT00004492
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
clotrimazole, hydroxyurea
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 31, 2026, 10:34 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Liposomal Bupivacaine Versus Bupivacaine Plain for Operative Pain Management of Forefoot Surgery

NCT04751344
View directory record Official record
Conditions
Liposomal Bupivacaine, Postoperative Pain, Forefoot Surgery, Opioid Use, Bunion
Interventions
Liposomal bupivacaine, Bupivacaine HCl
Drug
Lead sponsor
Alexandra Black
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 31, 2026, 10:34 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Setrusumab vs Placebo for Osteogenesis Imperfecta

NCT05125809
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Setrusumab, Placebo
Biological · Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
5 Years to 25 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Epidiolex in Obsessive Compulsive Disorder and Related Disorders

NCT04978428
View directory record Official record
Conditions
Obsessive-Compulsive Disorder, Trichotillomania (Hair-Pulling Disorder), Tourette Syndrome, Hoarding Disorder
Interventions
Cannabidiol
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 31, 2026, 10:34 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Regional Phenotyping of CF and Non-CF Bronchiectasis

NCT04793867
View directory record Official record
Conditions
Cystic Fibrosis, Non-CF Bronchiectasis
Interventions
Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 31, 2026, 10:34 AM EDT
Recruiting No phase listed Observational

Biologics And Clinical Immunology Cohort at Sinai

NCT04784364
View directory record Official record
Conditions
Immunological Disease, Autoimmune Diseases, Primary Immune Deficiency
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 31, 2026, 10:34 AM EDT
Not listed No phase listed Observational

Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)

NCT03053999
View directory record Official record
Conditions
Multiple Endocrine Neoplasia, Pancreatic Neuroendocrine Tumors, Hyperparathyroidism
Interventions
Genome Sequencing, Data Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 31, 2026, 10:34 AM EDT
Completed No phase listed Observational

Registry of Fabry Disease - A Multicenter Observational Study

NCT00055016
View directory record Official record
Conditions
Fabry Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 31, 2026, 10:34 AM EDT
Active, not recruiting Not applicable Interventional

Lung Transplant READY CF 2: A Multi-site RCT

NCT06030206
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Investigator-designed lung transplant education resource (Research Intervention), Publicly available transplant education resource (Attention-control)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 31, 2026, 10:34 AM EDT
Completed Phase 3 Interventional

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

NCT03584165
View directory record Official record
Conditions
Choroideremia, X-Linked Retinitis Pigmentosa
Interventions
BIIB111, BIIB112
Genetic
Lead sponsor
NightstaRx Ltd, a Biogen Company
Other
Eligibility
18 Years and older · Male only
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 31, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

NCT02269163
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
Immune Globulin Intravenous, Prometic's Immune Globulin Intravenous 10%
Biological
Lead sponsor
Prometic Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Irvine, California • Los Angeles, California • Centennial, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 31, 2026, 10:34 AM EDT
Recruiting No phase listed Observational

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

NCT06599619
View directory record Official record
Conditions
Melanoma
Interventions
Single agent, adjuvant anti-PD1 therapy
Drug
Lead sponsor
John Kirkwood
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 31, 2026, 10:34 AM EDT
Active, not recruiting Phase 4 Interventional

Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy

NCT03092011
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Clonidine, Morphine Sulfate
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
Up to 10 Days
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 31, 2026, 10:34 AM EDT